Spazmeks

International name Spazmeksa - trospium chloride

Composition

Each tablet contains 5 mg trospium chloride. As excipients used are: lactose monohydrate, corn starch, sodium starch glycolate, povidone (K 25) and stearic acid, colloidal silicon dioxide.  Spazmeks per pack

Coated tablets contain 15 or 30 mg trospium chloride. Other ingredients: microcrystalline cellulose, lactose monohydrate, stearic acid, sodium starch glycolate, povidone (K 25), corn starch, colloidal silicon dioxide, titanium dioxide, hypromellose

Therapeutic

M-holinoblokator, antispasmodic.

Pharmacological action Spazmeksa

Trospium chloride - a quaternary ammonium base from the group of anticholinergics. Competitive antagonist of acetylcholine at muscarinic receptors of postsynaptic membrane, has a relaxing effect on smooth muscle.

Faster than counterparts Spazmeks reduces the activity of the detrusor bladder, resulting in an increase in its volume, suppressed the urge to urinate, and thus significantly reduced the frequency of episodes of urge incontinence. Spazmeks a ganglion-blocking action and myotropic effect similar to papaverine. The central effects are absent.

Pharmacokinetics Spazmeksa

Following oral administration Spazmeksa maximum plasma concentration occurs within 4-6 hours. The half-life is on average 5 to 18 hours. The drug does not cumulate. Binding to plasma proteins is 50-80%. Only one of analog Spazmeks practically not subject to metabolism in the liver. Excreted by the kidneys, about 10% as a metabolite produced by hydrolysis of ester bonds, the remainder of the drug released in unaltered form.

Indications

  • Urgent need to urinate due to idiopathic detrusor hyperactivity, which can cause disturbances neuroregulation (injuries, and congenital and acquired diseases of the spinal cord, multiple sclerosis);
  • comprehensive treatment of cystitis symptoms with a peremptory;
  • enuresis - day and night;
  • pollakiuria;
  • mixed form of urinary incontinence.
  • idiosyncrasy trospium chloride or other components Spazmeksa;
  • retention of anatomical reasons (tumors, especially the structure of the urethra, prostate hyperplasia);
  • motility disorders or bowel obstruction;
  • angle-closure glaucoma;
  • tachyarrhythmia;
  • myasthenia gravis;
  • also contraindicated in children under 14 years.
  • diseases of the cardiovascular system, in which the undesirable increase in heart rate as tachycardia, ischemic heart disease, congestive heart failure;
  • thyrotoxicosis;
  • hiatal hernia, combined with reflux esophagitis;
  • diseases of the digestive system with obstructive conditions;
  • intestinal atony in elderly or debilitated patients;
  • paralytic ileus;
  • chronic inflammatory bowel disease (ulcerative colitis, Crohn's disease);
  • renal insufficiency;
  • autonomic neuropathy;
  • chronic lung disease;
  • toxemia of pregnancy;
  • Down's syndrome.

Contraindications

Take with caution in:

  • diseases of the cardiovascular system, in which the undesirable increase in heart rate as tachycardia, ischemic heart disease, congestive heart failure;
  • thyrotoxicosis;
  • hiatal hernia, combined with reflux esophagitis;
  • diseases of the digestive system with obstructive conditions;
  • intestinal atony in elderly or debilitated patients;
  • paralytic ileus;
  • chronic inflammatory bowel disease (ulcerative colitis, Crohn's disease);
  • renal insufficiency;
  • autonomic neuropathy;
  • chronic lung disease;
  • toxemia of pregnancy;
  • Down's syndrome.

Pregnancy and lactation

Instructions Spazmeksa says the possibility of taking pregnant or mothers reproaching the drug only if the mother's need for treatment exceeds potential risk for the baby. Clinical trials of Spazmeksa pregnant and nursing mothers have not been performed.

Spazmeks Dosage and instructions for use

Tablets Spazmeks to take food without chewing and drinking water. The drug Spazmeks appointed doctor depending on the patient's condition and the overall clinical picture. Spazmeks taken orally. The daily dose is 30 - 45 mg. and divided into three equal parts reception. By increasing the daily dosage to 45 mg. possible adoption of 30 mg in the morning and 15 mg in the evening. As with most analog Spazmeksa standard course of therapy is 2-3 months. With a positive effect in terms of the disappearance of symptoms, we recommend that the anti-treatment for 2-4 weeks. With longer therapeutic course, the attending physician shall review the need to continue or stop the treatment every 3-6 months. Patients with renal insufficiency, instruction Spazmeksa not recommended daily dose of 20 mg. Must not be exceeded daily dose of 135 mg.

Side effects Spazmeksa

Given a group action Spazmeksa parasympathetic can be observed: a decrease in sweating, dry mouth, constipation, feeling of fullness of the stomach, disturbance of accommodation, and tachyarrhythmia. Obtained on the practical application Spazmeksa reviews showed possible manifestation of side effects in the form of allergic reactions on the skin.

Overdose

Known from reviews Spazmeks therapy overdose symptoms are pronounced anticholinergic symptoms such as tachycardia, blurred vision, dry mouth, flushing of the skin. Overdose is treated Spazmeksa appointment of adsorbents and gastric lavage. Patients with glaucoma shows local administration of pilocarpine. When urinary retention catheterization is done. In severe cases, appointed holinomimetiki. If symptoms are not removed and is shown marked tachycardia with unstable circulation, beta-blockers are administered under the supervision of the ECG.

Interaction with other drugs Spazmeksa

The combined use of Spazmeksa with amantadine, tricyclic antidepressants, quinidine, antihistamines drugs, disopyramide, beta-agonists, anticholinergic enhances their effect.

Cautions

Before starting the treatment course Spazmeksa to exclude organic causes of urinary incontinence and pollakiuria, such as kidney or heart failure, swollen urinary tract.  Tablets Spazmeksa

If disturbed the function of the urethral sphincter, it is required to provide a full release of the bladder through a catheter.

Since according to the reviews Spazmeks may violate vision, it is recommended for the duration of therapy to refrain from driving vehicles and any potentially dangerous activity.

Form release Spazmeksa

Spazmeks available as a 5 mg tablet and coated tablets at 15 and 30 mg.

Storage conditions Spazmeksa

Spazmeks recommended to store in a dry, dark place, away from children. Storage temperature 15 - 25 ° C.

Shelf life 5 years.





Яндекс.Метрика